Regeneron Pharmaceuticals, Inc. (REGN)
Healthcare · Biotechnology · Data as of 2026-09-01
Bottom line
REGN is trading near its usual valuation, near its historical resistance zone, and recent volume suggests money flowing in. The picture is mixed, so it may be worth watching rather than acting on. Past patterns are not a guarantee of future results.
Valuation — Trading near its usual range (Yellow)
REGN trades at 19× earnings, roughly in line with its own 5-year average of 18× and below similar healthcare companies we track (29×, 52 peers). That is roughly what the market has typically paid for this stock. Its free-cash-flow yield is about 4.3%. Its current multiple sits around the 57th percentile of its own last five years — around the middle of its own range.
Price zones — Near its historical resistance zone (Red)
At $823.82, the stock is close to the upper end of its recent range. Over the past year REGN has traded between $541.00 and $847.00; its historical support zone sits near $730.02 and resistance near $847.00. It is above both its 50- and 200-day averages, which has historically signalled an uptrend.
52-week range $541.00–$847.00 · 50-day average $724.63 · 200-day average $730.02
Money flow — Money is flowing in (Green)
Recent trading in REGN shows more volume on rising days than falling days, a pattern often described as accumulation. Volume on up days has been about 2.8× volume on down days over the last 30 sessions.
About the company
Regeneron Pharmaceuticals, Inc. is a global biopharmaceutical enterprise focused on discovering, inventing, developing, manufacturing, and bringing to market medical treatments for a wide array of illnesses. Its therapeutic portfolio includes EYLEA, an injection used to treat various ophthalmic conditions such as wet age-related macular degeneration, diabetic macular edema, myopic choroidal neovascularization, diabetic retinopathy, and macular edema resulting from retinal vein occlusion (both central and branch).
一句话结论
REGN 估值接近其惯常水平，接近其历史阻力区，近期成交量显示资金正在流入。整体情况好坏参半，也许更适合先观察，而不是急于行动。过去的形态并不能保证未来的结果。
估值 — 处于其惯常的估值区间
REGN 目前的市盈率为 19×，大致持平于其自身 5 年平均的 18×，并且低于我们追踪的同类Healthcare公司（29×，52 家）。这大致就是市场以往为这只股票所付出的水平。其自由现金流收益率约为 4.3%。它当前的估值倍数大约位于自身过去五年分布的第 57 百分位——处于自身区间的中部。
价格区间 — 接近其历史阻力区
目前价格为 $823.82，接近其近期区间的上沿。过去一年 REGN 的价格在 $541.00 到 $847.00 之间波动；其历史支撑区在 $730.02 附近，阻力区在 $847.00 附近。它同时位于 50 日和 200 日均线上方，这在历史上通常对应上升趋势。
资金流向 — 资金正在流入
REGN 近期上涨日的成交量高于下跌日，这种形态常被称为吸筹。过去 30 个交易日，上涨日的成交量约为下跌日的 2.8×。
UnderTheLight 用直白的语言解释股票——估值、价格区间与资金流向。它只描述数据，不构成任何投资建议。
UnderTheLight explains stocks in plain English — valuation, price zones and money flow as traffic lights, recomputed nightly. It describes data; it is not investment advice and never recommends a trade.